Ikena Oncology (NASDAQ:IKNA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05, Zacks reports.
Ikena Oncology Trading Down 2.1 %
Shares of IKNA stock traded down $0.03 during trading hours on Monday, reaching $1.41. 57,653 shares of the company's stock were exchanged, compared to its average volume of 199,378. Ikena Oncology has a 1 year low of $1.22 and a 1 year high of $1.94. The stock has a market cap of $68.04 million, a PE ratio of -1.15 and a beta of 0.49. The stock's fifty day moving average price is $1.49 and its two-hundred day moving average price is $1.62.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on IKNA. HC Wainwright restated a "buy" rating and issued a $4.00 price objective on shares of Ikena Oncology in a report on Monday, November 11th. Wedbush restated a "neutral" rating and issued a $2.00 price target on shares of Ikena Oncology in a report on Monday, December 23rd.
View Our Latest Stock Report on Ikena Oncology
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Further Reading
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
